|
Treatment group
|
Overall (N = 721, P = 0.45)
|
HR (n = 143, P = NA)
|
HER2-amplified (n = 312, P = 0.42)
|
TN (n = 216, P = 0.59)
|
|---|
|
No. of patients
|
5-yr RFS (%)
|
No. of patients
|
5-yr RFS (%)
|
No. of patients
|
5-yr RFS (%)
|
No. of patients
|
5-yr RFS (%)
|
|---|
|
A no T
|
56
|
93 (86–100)
| |
–a
| |
–a
|
22
|
86 (73–100)
|
|
A + T
|
367
|
91 (88–94)
|
124
|
92 (87–97)
|
55
|
89 (80–98)
|
170
|
92 (87–96)
|
|
AT + HER2
|
227
|
93 (89–96)
| |
–a
|
220
|
93 (90–97)
| |
–a
|
|
PC
|
71
|
85 (78–94)
|
11
|
80 (58–100)
|
33
|
91 (81–100)
|
21
|
85 (72–100)
|
- Abbreviations: HR Hormone receptor, TN Triple-negative breast cancer, A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC provider choice
- aMissing cells < 10 patients
